Skip to main content
    N

    Nektar Therapeutics (NKTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $37.26
    +1.11 (+3.07%)

    Market Cap: $1.23B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    +11.23%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.07
    Range$-3.07 - $-1.71
    15 analysts
    EPS Revisions
    1
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.14+3.5%
    60d ago$-2.13+2.9%
    30d ago$-2.10+1.4%
    7d ago$-2.070.0%
    Current$-2.07
    Revenue Consensus
    $10M
    Range$10M - $12M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.50
    Range$-4.04 - $-1.30
    15 analysts
    Revenue Consensus
    $10M
    Range$8M - $13M
    15 analysts
    Last 12 of 39 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-2.50$-4.04 - $-1.30--15--
    Sep 26EST
    		-$-2.07$-3.07 - $-1.71--15
    2
    0
    30d
    		-
    Jun 26
    Reported Aug 13
    		$-1.23$-2.06$-2.74 - $-1.72+40.29%Beat4
    2
    0
    30d
    		+58.3%
    Mar 26
    Reported May 7
    		$-1.78$-1.48$-1.83 - $-1.22-20.27%Miss4
    1
    0
    30d
    		+50.7%
    Dec 25
    Reported Mar 12
    		$-1.78$-2.47$-3.07 - $-1.88+28.05%Beat2
    No revisions (30d)
    		-1086.7%
    Sep 25
    Reported Nov 6
    		$-1.87$-2.79$-3.23 - $-2.32+32.97%Beat3
    1
    0
    30d
    		+29.4%
    Jun 25
    Reported Aug 7
    		$-2.95$-3.13$-3.43 - $-2.81+5.75%Beat2
    0
    1
    30d
    		-5.0%
    Mar 25
    Reported May 8
    		$-3.61$-2.82$-2.84 - $-2.80-28.01%Miss3
    1
    0
    30d
    		-30.8%
    Dec 24
    Reported Mar 12
    		$-0.15$-0.13$-0.14 - $-0.11-15.38%Miss2
    1
    0
    30d
    		+31.8%
    Sep 24
    Reported Nov 7
    		$-2.65$-3.09$-3.14 - $-3.04+14.24%Beat7
    No revisions (30d)
    		+7.0%
    Jun 24
    Reported Aug 8
    		$-2.81$-3.01$-3.05 - $-2.98+6.64%Beat5
    No revisions (30d)
    		+30.6%
    Mar 24
    Reported May 9
    		$-2.76$-3.07$-3.10 - $-3.05+10.10%Beat3
    No revisions (30d)
    		+26.4%
    Dec 23
    Reported Mar 4
    		$-0.22$-0.21$-0.33 - $-0.15-4.76%Miss5
    No revisions (30d)
    		+31.3%
    Sep 23
    Reported Nov 7
    		$-2.85$-2.40$-2.47 - $-2.35-18.75%Miss7
    1
    0
    30d
    		+38.7%

    Key Metrics

    Valuation
    P/E Ratio-5.59EV/EBITDAN/A
    Price/FCF-5.26xFCF Yield-19.00%
    Profitability
    Profit Margin-287.80%Operating Margin-412.20%
    ROE-35.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-4.56x
    Current Ratio10.42xQuick Ratio10.42x
    Trading Statistics
    Beta1.42Avg Volume825.97K
    52-Week High$109.0052-Week Low$33.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$37.86
    SMA 20$37.84
    SMA 50$52.00
    SMA 200$65.03
    EMA 10$37.80
    EMA 20$39.85
    EMA 50$48.59
    EMA 200$58.03

    MACD

    Line: -3.64Signal: -4.58Hist: 0.95

    ADX

    ADX: 37.0+DI: 16.1-DI: 31.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down40.0
    PSAR$39.97

    Bollinger Bands

    Upper Band$39.97
    Lower Band$35.70
    %B Position1129%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    36.4

    Momentum Oscillators

    Stoch %K34.7
    Stoch %D39.5
    Williams %R-67.3
    ROC (10d)0.1%
    Momentum0.04
    CCI (20d)-73.3
    MFI (14d)59.1

    Volatility Measures

    ATR (14d)$2.18(5.9%)
    StdDev (20d)1.07
    Hist Vol55.4%(High)

    Volume Flow

    VWAP$37.09
    OBV56.1M
    AD Line14.7B
    CMF (20d)-0.104

    Volume Metrics

    Avg Vol (20d)762.3K
    Vol Ratio0.8x
    VWMA (20d)$37.86

    Pivot Points

    R3$40.35
    R2$39.36
    R1$37.75
    Pivot Point$36.76
    S1$35.15
    S2$34.16
    S3$32.55

    Advanced Oscillators

    TSI-35.99
    Ultimate Osc43.4
    KST-232.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$29.18M$24.12M$23.49M$21.64M$23.89M$24.14M
    Cost of Revenue$0$0$0$0$0$0$7.98M$4.43M$9.74M$8.53M$7.28M$12.43M
    Gross Profit$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$21.20M$19.69M$13.75M$13.11M$16.60M$11.71M
    Operating Expenses$52.47M$49.91M$49.47M$43.46M$47.41M$54.99M$6.85M$54.03M$63.52M$48.53M$50.11M$56.58M
    R&D$39.13M$35.68M$29.71M$27.25M$29.89M$30.48M$28.75M$35.03M$29.72M$27.41M$29.94M$24.07M
    SG&A$12.77M$13.44M$11.19M$16.07M$17.07M$24.35M$17.14M$18.96M$20.51M$20.15M$17.32M$21.15M
    Operating Income$-42,341,000$-39,054,000$-27,665,000$-31,672,000$-36,230,000$-44,535,000$14.35M$-34,345,000$-49,774,000$-35,427,000$-33,511,000$-44,864,000
    Interest Income$9.35M$4.24M$2.78M$2.82M$1.97M$2.87M$2.94M$3.44M$3.90M$4.22M$4.62M$5.21M
    Interest Expense$7.21M$7.94M$9.77M$6.05M$5.39M$4.97M$10.15M$6.02M$6.41M$5.53M$6.87M$5.91M
    Income Before Tax$-40,301,000$-43,090,000$-34,702,000$-35,021,000$-39,395,000$-46,369,000$7.00M$-37,048,000$-52,317,000$-36,837,000$-42,108,000$-45,898,000
    Income Tax Expense$2,000$64,000$31,000$-33,000$-188,000$52,000$-259,000$9,000$46,000$-35,000$-29,000$-61,000
    Net Income$-40,622,000$-44,904,000$-36,079,000$-35,522,000$-41,593,000$-50,882,000$7.26M$-37,057,000$-52,363,000$-36,802,000$-42,079,000$-45,837,000
    EBITDA$-45,855,000$-40,902,000$-29,407,000$-33,030,000$-36,625,000$-45,167,000$13.01M$-35,536,000$-50,935,000$-36,982,000$-38,206,000$-43,504,000
    EBIT$-42,441,000$-39,390,000$-27,709,000$-31,793,000$-35,970,000$-44,269,000$14.21M$-34,465,000$-49,810,000$-35,526,000$-39,858,000$-45,199,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NKTR

    News

    Nektar Therapeutics (ITH0.MU) Seasonal returns chart

    The article provides a seasonal returns chart for Nektar Therapeutics (ITH0.MU), showing its average monthly price return from 2016 to 2026. The stock was trading at 33.59 EUR, down 3.56% at the close.

    Yahoo Finance UK•11/3/26•Bearish

    Nektar Therapeutics (NKTR) Sets Q3 2026 Results for Nov. 12 After Close

    Nektar Therapeutics (NKTR) will announce its Q3 2026 financial results on Thursday, November 12, after the U.S. market closes...

    TradingView•10/27/26•Neutral

    Nektar Therapeutics to report Q3 2026 earnings on Nov 12 with CEO conference call

    Nektar Therapeutics will announce its financial results for the third quarter ending September 30, 2026, on November 12 after U.S. markets close. CEO Howard Robin will host a conference call at 5:00 p.m. Eastern Time...

    Pluang•10/27/26•Neutral

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Nektar Therapeutics announced inducement grants of stock options and restricted stock units to 24 newly hired non-executive employees. These grants were made outside of the company's 2005 Equity Incentive Plan as...

    Moomoo•10/24/26•Neutral

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Nektar Therapeutics announced that its Organization and Compensation Committee granted non-qualified stock options for 45,750 shares and 2,775 restricted stock units (RSUs) to sixteen new employees. These grants were...

    PR Newswire•10/23/26•Neutral

    NKTR Valuation and Fair Value

    P/E
    -5.6x
    Forward P/E
    34.0x
    P/FCF
    -5.3x
    PEG
    0.3x
    P/B
    1.4x
    See GNG's fair value

    NKTR Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -412.2%
    Net margin
    -287.8%
    ROE
    -35.8%
    FCF yield
    -19.0%

    NKTR Competitors

    CompanyTicker
    Omeros CorporationOMER
    Procept Biorobotics CorpPRCT
    InnovAge Holding CorpINNV
    Tourmaline Bio Inc.TRML
    Tandem Diabetes Care IncTNDM
    Silence Therapeutics PLCSLN
    Artivion IncAORT
    Compass Pathways PlcCMPS

    Sector: Healthcare

    NKTR Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    1
    Buy
    9
    Hold
    2
    Sell
    0
    Strong Sell
    0

    NKTR Bull Case vs Bear Case

    Bull case

    • 83.3% of NKTR's analyst ratings are Buy or Strong Buy.

    Bear case

    • NKTR has a -287.8% net profit margin.
    • NKTR's quarterly revenue changed -9.3% year over year.

    NKTR Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    7.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    NKTR Earnings Date

    NKTR reports Nov 12, 2026, after the close. The date is confirmed.

    NKTR Earnings Call

    The latest NKTR earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    NKTR ETF Holders

    GNG tracks 7 ETFs that hold NKTR. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.37% of the fund
    2. Fidelity Growth Company Fund (FDGRX), 0.10% of the fund
    3. Vanguard Health Care Index Fund ETF Shares (VHT), 0.02% of the fund
    4. Vanguard Extended Market Index Fund ETF Shares (VXF), 0.01% of the fund
    5. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for NKTR

    See insider activity

    Frequently Asked Questions About NKTR

    When does NKTR report earnings?

    Nektar Therapeutics (NKTR) is confirmed to report earnings on Nov 12, 2026.

    Does NKTR pay dividends?

    Nektar Therapeutics (NKTR) does not currently pay a regular dividend.

    What is NKTR's market cap?

    Nektar Therapeutics (NKTR) has a market capitalization of $1.23B with a current stock price of $37.26.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In